Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 805 across all filing types
Latest filing 2011-12-07 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
SANTARUS AND PHARMING ANNOUNCE ORAL PRESENTATIONS OF RETROSPECTIVE ANALYSES OF DATA FROM RHUCIN CLINICAL PROGRAM AT WORLD ALLERGY CONGRESS
Regulatory Filings Classification · 94% confidence The document is a press release dated December 7, 2011, announcing that Pharming and Santarus presented retrospective analyses of data from the RHUCIN clinical program at the World Allergy Congress. It details efficacy and safety data presented orally at a conference and provides updates on the ongoing Phase III study and product background. This format—a joint announcement about scientific data presentation at a medical conference—is characteristic of an Earnings Release (ER) or a general press release announcing corporate/scientific updates. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it focuses on announcing key scientific/clinical progress, it best fits the Earnings Release (ER) category, which often includes operational and clinical highlights, or potentially Regulatory Filings (RNS) if it were less focused on specific results. Given the detailed presentation of clinical efficacy data and the announcement structure, ER is the most appropriate fit for a major operational/scientific update announcement, even though it's not strictly quarterly earnings.
2011-12-07 English
Pharming reports financial results third quarter 2011
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the third quarter of 2011, containing detailed financial highlights, operational updates, outlook, and unaudited consolidated financial statements (Statement of Financial Position and Statement of Income). It is not merely an announcement of a report, but the report itself, covering a period shorter than a full fiscal year. 9M 2011
2011-11-17 English
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the third quarter of 2011, containing detailed financial highlights, operational updates, outlook, and unaudited consolidated financial statements (Statement of Financial Position and Statement of Income). It is not merely an announcement of a report, but the report itself, covering a period shorter than a full fiscal year. 9M 2011
2011-11-17 English
Pharming And Santarus Announce Presentation Of Retrospective Analysis Of Data From Clinical Studies Of Rhucin
Regulatory Filings Classification · 94% confidence The document is a press release announcing that data from clinical studies of the drug RHUCIN will be presented at the '2011 Annual Meeting of the American College of Allergy, Asthma & Immunology' (ACAAI). It details the content of the oral presentation and poster session regarding efficacy and immuno-safety data. This is not a formal regulatory filing (like 10-K or IR), nor is it a transcript (CT) or a formal earnings release (ER). It is an announcement related to scientific findings being presented at a professional meeting, which often falls under Investor Relations or general corporate news. Since the core content is about the presentation of scientific/clinical data at a major meeting, it is best classified as an Investor Presentation (IP) or a general Regulatory Filing (RNS) if IP is too specific for scientific presentation announcements. However, given the detailed nature of the findings being announced (efficacy endpoints, safety data), it functions as a preview or summary of data that would typically be in an Investor Presentation or a scientific update. Since the document is a press release announcing the presentation of data, and not the presentation slides themselves, it is closest to an Earnings Release (ER) in format (press release announcing results/updates) but the content is scientific presentation news. Given the options, and recognizing this is a corporate announcement about scientific data dissemination, it is most closely aligned with an Investor Presentation (IP) in terms of content focus, or potentially a Regulatory Filing (RNS) if it's considered general news. Since it is announcing the *presentation* of detailed clinical findings, which is a key activity for investors to track, IP is a strong candidate. However, if we strictly follow the definitions, it is an announcement of scientific data dissemination, not the presentation itself. It is not a formal financial report. It is a corporate announcement. Given the options, and the focus on clinical data presentation, I will lean towards Investor Presentation (IP) as the most relevant category for investor-facing scientific updates, although RNS is a possibility if IP is reserved strictly for slide decks. Given the context of financial reporting databases, updates on clinical trial data presentation are often grouped with investor materials. I will select IP.
2011-11-04 English
Ruconest® launched in the Netherlands
Regulatory Filings Classification · 95% confidence The document is a press release dated August 31, 2011, announcing the launch of the drug Ruconest® in the Netherlands following regulatory approval. It details product information, market availability, and company background. This type of announcement, focusing on a specific business event (product launch/regulatory milestone) and providing key operational updates, fits best under the general category for regulatory announcements or specific business updates. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a formal shareholder communication (DEF 14A, PSI), it is classified as a general Regulatory Filing (RNS) as it is a formal announcement to the market about a significant operational event, which often serves as a catch-all for non-standard press releases that are not covered by more specific codes like DIV or CAP.
2011-08-31 Dutch
Pharming grants SOBI additional territories for the commercialisation of Ruconest®
Regulatory Filings Classification · 91% confidence The document is a press release dated August 29, 2011, announcing a commercialization agreement regarding the drug Ruconest®. It details the expansion of distribution rights for SOBI across European territories. This type of announcement, which concerns business operations, partnerships, and product commercialization updates, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, DIRS). It is a general business update or regulatory announcement. Since it is not a formal financial report, a transcript, or a specific corporate governance filing, the most appropriate general category is 'Regulatory Filings' (RNS), which serves as a catch-all for significant, non-standard announcements.
2011-08-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.